Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

AegirBio’s chairman has announced his intention to leave the board of directors

Anders Ingvarsson, board member of AegirBio AB (“AegirBio” or the “Company”) since 2019, has announced his intention to resign as board member and chairman of AegirBio. The reason for the decision is personal reasons.Anders Ingvarsson will leave the board in connection with the extraordinary general meeting that the board intends to convene shortly, in accordance with the press release published earlier today. Notice of the extraordinary general meeting will be published in a separate press release. “I am pleased to note that the financing solution we have developed will facilitate the

BioStock: Prolight Diagnostics’ collaboration with G&H | ITL propels development

Prolight Diagnostics have appointed G&H | ITL for the development of its innovative point-of-care system, Psyros. The development project started in early 2023 and is steadily progressing. BioStock reached out to G&H’s CEO Charlie Peppiatt and Prolight Diagnostics’ Head of Engineering, Paul Monaghan, to gain further insight into the current status of development.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/prolight-diagnostics-collaboration-with-gh-itl-propels-development/ This is a press release from BioStock - Connecting

AegirBio enters into a conditional agreement on a MSEK 45 loan facility with Atlas Special Opportunities and an agreement to amend the outstanding convertible bonds, subject to EGM approval

AegirBio AB (“AegirBio” or the “Company”) has today entered into a conditional agreement on a loan facility with Atlas Special Opportunities, LLC (“Atlas”) under which the Company can call for loans in seven (7) tranches (hereinafter “Tranches” or each “Tranche”) in an aggregate nominal amount of SEK 45.00 million before deduction of set-up fee (the “Loan Facility”) and transaction costs. The Loan Facility has been procured in order to secure continued financing of the Company’s operations, and to expedite the Company’s grant-awarding RADx® project under the auspices of the National

Acquisition

09 April 2024                                                                                                                Everest Global plc (“Everest” or the “Company”) Acquisition of 33% of Ace Jumbo Ventures Limited, a Hong Kong Type 9 and Type 4 Licence Holder The Company is pleased to announce that on 08 April 2024 it entered into a share purchase agreement (“SPA”) with Giga Treasure Limited (the “Seller”), to acquire 33 per cent. of the issued share capital of Ace Jumbo Ventures Limited (the “Target”) for US$20,000 in cash (the “Transaction”). The Target is the parent

Cereno Scientific announces extended patent protection in Europe for CS585 program

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that a patent has been approved (Notice of Allowance) in the first patent family for the preclinical Prostacyclin Receptor Agonist program, which includes drug candidate CS585. The patent expands the patent protection for the Prostacyclin Receptor Agonist program to also include Europe, one of the largest markets for cardiovascular disease.“I am pleased to announce the second patent in Europe for our preclinical Prostacyclin

Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test – moving forward towards model-development study

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, announces today that the company has successfully developed accurate and precise assays to measure targeted proteins for its next-generation test.    As announced in November 2023 , Immunovia successfully finalized a discovery study that evaluated nearly 3,000 proteins to identify 15 promising protein

CLS receives second order from the National Institutes of Health Clinical Center in the US

Lund, Sweden April 9, 2024 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today announced that it has received its second order from the National Institutes of Health Clinical Center in the US for its TRANBERG Thermal Therapy System accessories.The order of single-use sterile instruments includes introducers, temperature probes, and unique, non-cooled laser applicators that will be used to assess the clinical utility of CLS’s TRANBERG Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male

Notice of Annual General Meeting in Inwido AB

The shareholders of Inwido AB (publ), Reg. No. 556633-3828, are hereby invited to attend the Annual General Meeting (“AGM”) to be held on Thursday 16 May 2024 at 15.00 CEST at Studio, Nordenskiöldsgatan 24,  Malmö, Sweden. Registration of attendance commences at 14.30 CEST. The notice is available at www.inwido.com where shareholders also can notify the company of their intention to attend the AGM. Complete documentation for the AGM will be available at Inwido’s head office and on www.inwido.com no later than from Thursday 25 April 2024.The Board of Directors has decided that shareholders

Notice for the Annual General Meeting of ITAB Shop Concept AB (publ)

ITAB Shop Concept AB (publ), Corp. Reg. No. 556292-1089 (“ITAB” or the “Company”), with its registered office in Jönköping Municipality, hereby convenes the Annual General Meeting to be held on Wednesday, 15 May 2024 at 3:00 p.m. CEST at ITAB’s premises at Instrumentvägen 2 in Jönköping. Entry to the meeting will begin at 2:30 p.m. CEST.REGISTRATION AND NOTIFICATIONShareholders who wish to participate in the Annual General Meeting must be included in the share register prepared by Euroclear Sweden AB based on the circumstances prevailing on Monday, 6 May 2024. Shareholders must also

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS09 April 2024 at 09:15NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: BINGAB Barents Investment Group ABPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Johan LarssonPosition: Chief Executive OfficerIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 57706/5/4 ____________________________________________Transaction date: 2024-04-05

2020 Bulkers Ltd. (2020) – Financing update and special dividend

Oslo, Norway, April 9, 2024 Refinancing and amendment of Term Loan Facility The Company is pleased to announce its agreement to refinance and amend its US$162.5 million Term Loan Facility maturing in March 2027. Pursuant to the new agreement, the Company will repay US$27.5 million of the outstanding amount under the Term Loan Facility, which will be replaced with a new non-amortizing US$112.5 million Loan Facility maturing in April 2029. The new Loan Facility has the following main amendments: · Interest rate of SOFR+195 bps, down from SOFR + credit adjustment spread of 0.

Watches and Wonders and Colors

Diversity! In Geneva, NOMOS Glashütte presents the iconic Tangente model in 31 different color compositions at once.GLASHÜTTE, APRIL 9, 2024. An icon is an icon is an icon. What is there left to say? NOMOS Glashütte has long been known for its color expertise. But now, at Watches and Wonders in Geneva, the watchmaking company is presenting its bestseller Tangente, which has remained unchanged for more than three decades, in color. Or rather—in colors. The special edition Tangente 38 date – 175 Years Watchmaking Glashütte is a collection of 31 different colorful versions of the classic watch,

Net Asset Value(s)

RIZE SUSTAINABLE FUTURE OF FOOD UCITS ETF (LEI: 635400XEUXEEYJDGAN37) Final Net Asset Value FUND NAME NAV ISIN NAV DATE RIZE SUSTAINABLE 4.0094 USD IE00BLRPQH01 08 April 2024FUTURE OF FOOD UCITS ETF RIZE CYBER SECURITY AND DATA PRIVACY UCITS ETF (LEI: 635400X9AIBDQQ6PQR51) Final Net Asset Value FUND NAME NAV­ ISIN NAV DATERIZE CYBER SECURITY AND 7.3594 USD IE00BJXRZJ40 08 April 2024DATA PRIVACY UCITS ETF RIZE DIGITAL PAY ECONOMY ETF (LEI: LEI 635400LYAWYIKLU7RN49) Final

Repurchases of shares during week 14, 2024

Between April 2 2024 and 5 April 2024 Attendo AB (LEI code 549300KEJDL2FNITUW65) (“Attendo”) has repurchased in total 155,012 own shares (ISIN: SE0007666110) as part of the repurchase program initiated by the Board.The repurchases form part of the repurchase program of a maximum of 16,138,659 own shares for a total maximum amount of SEK 110,000,000 that Attendo announced on 8 February 2024. The repurchase program, which runs between 9 February 2024 and 24 April 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (

Half-year Report

Fidelity Asian Values PLC   Half-Yearly Results for the six months ended 31 January 2024 Financial Highlights · During the six months ended 31 January 2024, Fidelity Asian Values PLC reported a Net Asset Value (NAV) total return of -2.4% and an Ordinary Share Price total return of -2.5%.   · The Comparative Index, the MSCI All Countries ex Japan Small Cap Index, returned +3.6%.   · The Portfolio Managers remain focused on investing in good business, run by good management teams, available at a suitable margin of safety.   Contacts For further

Himalaya Shipping Ltd. (HSHP) – Commercial Update and Key Information Relating to the Cash Distribution for March 2024

Hamilton, Bermuda, April 9, 2024 Commercial update: In March 2024, Himalaya Shipping Ltd. (“Himalaya,” or the “Company”) achieved average time charter equivalent (“TCE”) earnings of approximately US$34,300 per day, gross[1], including average daily scrubber and LNG benefits on eight vessels of approximately US$3,100 per day. The Company’s six vessels trading on fixed time charters earned approximately US$28,800 per day, gross, including average daily scrubber and LNG benefits on five vessels. The Company’s three vessels trading on index-linked time charters earned approximately US$45,

Lesjöfors Group becomes first spring manufacturer to be validated by SBTi

In a first for the spring manufacturing industry, the Lesjӧfors Group’s near-term climate emission reduction targets have officially been validated by the Science Based Target initiative (SBTi).Major Milestone Achieved  The validation by the SBTi (the official body for setting climate targets) establishes the Lesjӧfors Group as the only spring and pressing manufacturer in the world to achieve the validation, confirming the Lesjӧfors Group’s commitment to achieving the Paris agreement goals of limiting global warming to 1.5 ̊C above pre-industrial levels.  Lesjӧfors Ambitious Reduction

Arctic Bioscience – Annual report 2023

Arctic Bioscience has today released its Annual Report 2023, including the Board of Directors report and financial statements. The report and annual accounts were approved by the Board of Directors after close of business on 8[th] of April 2024.The report is attached to this stock notice and is available on the company’s website. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.

Grant of share options to primary insiders in Atea ASA

On 8 April 2024, key employees in the Atea Group were granted share options in Atea ASA. The following primary insiders were granted options (in alphabetic order, by last name): Arunas Bartusevicius (Managing Director, Atea Baltics) has been granted 70,000 options vesting on December 15, 2027. Following the grant, Arunas Bartusevicius holds 170,290 shares, 280,000 options and 48 RSUs in Atea ASA. Kathrine Forsberg (Managing Director, Atea Denmark) has been granted 100,000 options vesting on December 15, 2027. Following the grant, Kathrine Forsberg holds 90 shares, 340,000 options

2020 Bulkers Ltd. (2020) – Commercial update and key information relating to the dividend for March 2024

Oslo, Norway, April 9, 2024 Commercial update: In March 2024, the Company achieved average time charter equivalent rate (“TCE")* of approximately US$35,000 per day, gross. The Company had 198 operational days in March 2024. The Company’s five vessels trading on index-linked time charter earned approximately US$45,000 per day, gross, including average daily scrubber benefits of approximately US$3,600 per day. The Company’s three vessels trading on fixed time charter earned approximately US$23,800 per day, gross, including average daily scrubber benefits of approximately US$4,400 per

Leftover fabrics become a new Newbie collection

With sustainability at the very heart of the brand's inception, the creation of collections from remnant fabrics from production is a natural part of Newbie's customer offering. Now it's time again, during April the next collection will be released called "Rescued fabrics. To be loved again". "One of Newbie's starting points is to always think long-term and timeless and create garments in certified materials that can be inherited, we want to inspire and encourage for the clothes to be used for a long time. But also to make use of all the material. That's why we started creating

Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer

Press release Nanoform Finland Plc April 9, 2024 09.00 EEST / 08.00 CEST Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer Helsinki, Finland – April 9, 2024 – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced a collaboration with PlusVitech, a biotechnology company developing treatments for cancer, to use Nanoform’s state-of-the-art nanomedicine technology to repurpose the anti-nausea medicine aprepitant as a treatment for lung cancer. The development program will include nanoforming the current

Invitation to Kesko’s Q1 interim report briefing on Thursday 25 April 2024

A stock exchange release concerning Kesko's interim report for January-March 2024 will be published on Thursday, 25 April 2024, at around 8.00 am (EET/EEST).A teleconference in English will be held at 9.00 am (EET/EEST). It will include a presentation by the President and CEO Jorma Rauhala, after which the Presidents of the three business divisions will be available for questions. The link to the teleconference is available at kesko.fi/report-centre. Registration is required for the teleconference. After the registration you will be provided phone numbers and a conference ID to access

There are no items matching the current filter
There are no more items matching the current filter
Back to top